Glenza 80mg Capsule

Glenza 80mg Tablet is an anticancer medicine. It contains Enzalutamide (80mg) as an active ingredient that belongs to the second-generation nonsteroidal antiandrogen class of drugs. It prescribes to treat prostate cancer in men at various stages. It may also be used to treat some other conditions like PCOS, as determined by the doctor.

Glenza works by blocking the effects of male hormones such as testosterone to slow down the growth and multiplication of cancer cells. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose

• Prostate cancer
• Polycystic ovarian syndrome (PCOS)
• Excessive hair growth

Glenza 80mg Capsule may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Headache
• Hot flashes
• Weakness
• High blood pressure
• Fatigue
• Decreased appetite
• Constipation
• Dry skin
• Itching
• Fall
• Fracture

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Glenza 80mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.
  
  

• Glenza 80mg Tablet contains Enzalutamide (80mg) as an active ingredient that belongs to the second-generation nonsteroidal antiandrogen class of drugs.
• It works by blocking the action of a particular enzyme to reduce the production of male hormone like testosterone. As a result, by controlling the production of hormone it slows down the progression of cancer.
  
  

• Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M. ... & Shore, N. D. (2023). Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. New England Journal of Medicine, 389(16), 1453-1465. https://pubmed.ncbi.nlm.nih.gov/37851874/
• Hoffman-Censits, J., & Kelly, W. K. (2013). Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clinical Cancer Research, 19(6), 1335-1339. https://pubmed.ncbi.nlm.nih.gov/23300275/
• Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., Van Poppel, H., & Joniau, S. (2014). Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature reviews urology, 11(12), 712-716. https://pubmed.ncbi.nlm.nih.gov/25224448/
• Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S. ... & Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131. https://pubmed.ncbi.nlm.nih.gov/31157964/
• Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., ... & Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424-433. https://pubmed.ncbi.nlm.nih.gov/24881730/